Cardio Diagnostics utilizes an AI-driven Multi-Omics™ engine to provide precision cardiovascular risk assessment and early diagnosis through epigenetic and genetic analysis. Their technology enables healthcare providers to predict the three-year risk of coronary heart disease events, improving patient management and optimizing treatment outcomes.
Funding
$11.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular diseases remain a leading cause of mortality, often due to late detection and intervention. Traditional diagnostic methods may not provide a comprehensive risk assessment, hindering personalized treatment strategies. There is a need for more precise and early diagnostic tools to improve patient outcomes and reduce healthcare costs associated with cardiovascular events.
Solution
Cardio Diagnostics offers an AI-driven Multi-Omics™ engine that analyzes both epigenetic and genetic markers to provide a comprehensive cardiovascular risk assessment. Their technology enables early diagnosis and prediction of a patient's three-year risk of experiencing a coronary heart disease event, such as a heart attack. By integrating genome-wide genetic, epigenetic, and clinical data, the platform generates actionable predictive models. This approach facilitates personalized care management, monitors treatment effectiveness, and optimizes health outcomes through precise measurements and scalable techniques.
Target Audience
The primary target audience includes healthcare providers, provider organizations, employers, brokers and benefits consultants, government entities, and clinical researchers focused on cardiovascular disease management and prevention.
Features
- AI-driven Multi-Omics™ engine integrating genetic, epigenetic, and clinical data
- Predictive models for assessing the three-year risk of coronary heart disease events
- Clinical blood tests for the detection and management of coronary heart disease
- Digital and Taqman PCR-based assays for precise measurement of epigenetic and genetic markers
- Scalable platform for seamless integration and analysis of diverse datasets
- Non-clinical solutions include a cardiovascular risk intelligence platform for healthcare stakeholders
- Research use only (RUO) platform to support the discovery and validation of novel biopharmaceuticals